Achaogen: company management


	Founders Management Board of Directors Advisors


	J. Kevin Judice, Ph.D. - Chief Executive Officer
	Dr. Judice was most recently head of the medicinal chemistry group at Genentech, where he provided strategic direction to the growing small molecule effort within the company. Prior to Genentech, he served as Vice President of Medicinal Chemistry at Theravance, Inc. (formerly Advanced Medicine, Inc.), a role in which he had line responsibility for more than 90 of the company's roughly 180 scientists. During his early years at Theravance, Dr. Judice served as project team leader for the group which discovered telavancin (TD-6424), a rapidly bactericidal agent which is currently in Phase 2 human clinical trials. Subsequent to that, Dr. Judice oversaw all of the medicinal chemistry efforts during a period in which two more compounds were advanced to clinical trials — including an asthma agent which was successful in Phase 2 clinical trials and a compound (currently in Phase 1) to treat overactive bladder disorders. An additional five compounds have been nominated as development candidates by Theravance since its founding in 1997. Dr. Judice received his bachelor's degree at Texas A&M, his Ph.D. at UCLA, and was awarded an NIH postdoctoral fellowship at Berkeley.
	Jon B. Bruss, MD, MSPH, MBA, FAAP - Chief Medical Officer
	Dr. Bruss, a specialist in infectious diseases, joined Achaogen in early 2008. He has broad experience in anti-infective and biologics drug development (Phases I-IV), participating in the registration of anti-infective drugs in US, Europe, and Japan, including negotiations with regulatory authorities in these countries. He has held positions of increasing responsibility at Pharmacia, Pfizer, and PediaMed Pharmaceuticals, where he was Chief Medical Officer and Executive Vice President. Prior to joining Achaogen, he served as President of the consulting firm Alarus Development International, which specializes in anti-infective drug development. He also has experience in the US and internationally in clinical pediatrics and public health management. He received his MD from the University of New Mexico and then completed a pediatric residency at the Children’s Hospital of New Mexico. He completed a fellowship in pediatric infectious diseases at Harvard Medical School and Boston Children’s Hospital, and then remained on faculty doing anti-infective and vaccine related research. He received a MSPH degree in parasitology and tropical medicine from Tulane University, School of Public Health and a MBA degree from Kellogg School of Business Management, Northwestern University. He has a solid understanding of principles of scientific research and commercialization of medicines.
	Philip A. Patten, Ph.D. - Senior VP, Biology
	Dr. Patten was most recently Vice President of Science and Technology at Maxygen. He was a founding scientist at Maxygen where he led diverse projects and developed the core gene shuffling technology over a period of over eight years in research. He led the team that discovered and partnered a gene shuffled interferon that was licensed by Roche for development as a next generation therapeutic for HCV. Dr. Patten received his bachelor's degree in Biology at the California Institute of Technology and his Ph.D. at Stanford University. He was awarded a Damon Runyon Postdoctoral Fellowship at U.C. Berkeley where he did pioneering work on the structural basis of antibody affinity maturation and directed evolution of antibodies in the laboratory of Professor Peter Schultz.
	Donald E. Schmidt, Ph.D. - VP, Analytical Chemistry
	Most recently, Dr. Schmidt was the head of the analytical chemistry group at Theravance, Inc. This group of 25 people was responsible for the physical characterization of research compounds, for bioanalytical chemistry, for high throughput purification and for the analytical chemistry of compounds in Phase 1 and 2. In particular, Dr. Schmidt was involved in the research aspects, the manufacture, and the analytical chemistry of Theravance's antibiotic telavancin which has now progressed to Phase 3 trials. Previous to Theravance, he was the head of the analytical department at Telik, Inc and, before that, created the HPLC column line for the Rainin Instrument Company. Dr. Schmidt received his B.S. from Iowa State University, his Ph.D. from the California Institute of Technology and was an NIH postdoctoral fellow at Harvard University. In addition, he was an Associate Professor at the University of Windsor and spent 2 years at the Institute of Chemical Analysis at Northeastern University.
	Heinz E. Moser, Ph.D. - Senior VP, Chemistry
	Dr. Moser brings his experience in drug discovery and medicinal chemistry to Achaogen. He has previously held various managerial positions with Ciba and Novartis and prior to joining the company, he was Chief Technical Officer and Vice President of Chemistry at GeneSoft (now Oscient), a biotech company dedicated to antibacterial drug discovery and development. Dr. Moser received his Ph.D. from the Federal Institute of Technology (ETH) in Zurich and served as a post-doctoral fellow at the California Institute of Technology. He is author of over 30 manuscripts in peer-reviewed journals, co-inventor of 10 published patent applications and recipient of the Ruzicka Award.
	John F. Hollway - Senior VP, Corporate Development
	Mr. Hollway was most recently the Vice President of Operations, Vice President of Strategy & Corporate Development, and Chief Privacy Officer for Acurian, Inc., a clinical trials recruitment company. Mr. Hollway built Acurian's industry-leading patient database to its current level of over 8.5 million individuals, and he conceived of and built the company's clinical data services, AcuChart and AcuPatientRx. He was also responsible for the overall management of client projects and the protection and the establishment and maintenance of industry-leading data management standards and procedures. Prior to joining Acurian, Mr. Hollway was the General Manager in charge of wireless strategy and product development for Shared Medical Systems Corp, now Siemens Medical Systems (SMS). Before that, Mr. Hollway was an attorney at Morgan, Lewis & Bockius LLP. There he managed numerous complex civil litigation cases, with special emphasis on contractual disputes and business planning to avoid future litigation. Mr. Hollway holds a J.D. with honors from George Washington University, and a B.A. from the University of Pennsylvania.